Recent Updates
Recently added Catalysts
MYGN Positive Sentiment Score: 70/100

Myriad Genetics to Release First Quarter Financial Results on May 3, 2023

Key Takeaway: Myriad Genetics, Inc. will report its first quarter earnings for 2023 on May 3, 2023, with a conference call scheduled for 4:30 p.m. ET. The financial results will be made available after market close on the same day. During the call, Myriad's management will present an overview of the company’s performance up to March 31, 2023, providing insights into both financial data and business developments.

Market Sentiment Analysis

POSITIVE FACTORS

  • Myriad Genetics is recognized as a leader in genetic testing and precision medicine.
  • The upcoming earnings call suggests active communication with investors.
  • The company provides genetic tests that enhance patient care and lower healthcare costs.

Full Press Release Details

SALT LAKE CITY, April 26, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its first quarter earnings conference call on Wednesday May 3, 2023 at 4:30 p.m. ET. The company’s quarterly earnings will be released the same day after the market closes.
During the call, Myriad management will provide a financial overview and business update of the company’s performance for the period ending March 31, 2023.
Conference Call and Webcast
The dial-in number for domestic callers is 1-800-582-4086. International callers may dial 1-212-231-2905. All callers will be asked to reference reservation number 22026701. An archived replay of the call will be available for seven days by dialing 1-800-633-8284 and entering the reservation number above. The conference call and slide presentation will be available through a live webcast at www.myriad.com.
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.
Media Contact: Investor Contact:
Glenn Farrell Matt Scalo
(385) 318-3718 (801) 584-3532
PR@myriad.com IR@myriad.com

Tags

Frequently Asked Questions

When is Myriad Genetics' Q1 earnings call?

The Q1 earnings call is scheduled for May 3, 2023, at 4:30 p.m. ET.

How can I listen to the earnings call?

You can listen via dial-in at 1-800-582-4086 or through a live webcast at www.myriad.com.

What will be discussed in the earnings call?

Management will provide a financial overview and business update for Q1 2023.

Is there a replay available of the earnings call?

Yes, an archived replay will be available for seven days by dialing 1-800-633-8284.

What services does Myriad Genetics provide?

Myriad specializes in genetic testing and precision medicine to enhance patient care.

Last updated: Apr 26, 2023